CoChat

Evaluation of the Safety and Immunogenicity of the RTS,S/AS01EMalaria Candidate Vaccine When Integrated in the Expanded Program of Immunization

Agnandji, Selidji T., Asante, Kwaku Poku, Lyimo, John, Vekemans, Johan, Soulanoudjingar, Solange S., Owusu, Ruth, Shomari, Mwanajaa, Leach, Amanda, Fernandes, Jose, Dosoo, David, Chikawe, Maria, Issifou, Saadou, Osei‐Kwakye, Kingsley, Lievens, Marc, Paricek, Maria, Apanga, Stephen, Mwangoka, Grace, Okissi, Blaise, Kwara, Evans, Minja, Rose, Lange, Jorn, Boahen, Owusu, Kayan, Kingsley, Adjei, George, Chandramohan, Daniel, Jongert, Erik, Demoitié, Marie‐Ange, Dubois, Marie‐Claude, Carter, Terrel, Vansadia, Preeti, Villafana, Tonya, Sillman, Marla, Savarese, Barbara, Lapierre, Didier, Ballou, William Ripley, Greenwood, Brian, Tanner, Marcel, Cohen, Joe, Kremsner, Peter G., Lell, Bertrand, Owusu‐Agyei, Seth, Abdulla, Salim · 2010 · The Journal of Infectious Diseases
Cited by 73

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The RTS,S/AS01(E) malaria candidate vaccine is being developed for immunization of African infants through the Expanded Program of Immunization (EPI). METHODS: This phase 2, randomized, open, controlled trial conducted in Ghana, Tanzania, and Gabon evaluated the safety and immunogenicity of RTS,S/AS01(E) when coadministered with EPI vaccines. Five hundred eleven infants were randomized to receive RTS,S/AS01(E) at 0, 1, and 2 months (in 3 doses with diphtheria, tetanus, and whole-cell pertussis conjugate [DTPw]; hepatitis B [HepB]; Haemophilus influenzae type b [Hib]; and oral polio vaccine [OPV]), RTS,S/AS01(E) at 0, 1, and 7 months (2 doses with DTPwHepB/Hib+OPV and 1 dose with measles and yellow fever), or EPI vaccines only. RESULTS: The occurrences of serious adverse events were balanced across groups; none were vaccine-related. One child from the control group died. Mild to moderate fever and diaper dermatitis occurred more frequently in the RTS,S/AS01(E) coadministration groups. RTS,S/AS01(E) generated high anti-circumsporozoite protein and anti-hepatitis B surface antigen antibody levels. Regarding EPI vaccine responses upon coadministration when considering both immunization schedules, despite a tendency toward lower geometric mean titers to some EPI antigens, predefined noninferiority criteria were met for all EPI antigens except for polio 3 when EPI vaccines were given with RTS,S/AS01(E) at 0, 1, and 2 months. However, when antibody levels at screening were taken into account, the rates of response to polio 3 antigens were comparable between groups. CONCLUSION: RTS,S/AS01(E) integrated in the EPI showed a favorable safety and immunogenicity evaluation. Trial registration. ClinicalTrials.gov identifier: NCT00436007 . GlaxoSmithKline study ID number: 106369 (Malaria-050).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/656190

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 73

Metadata

Authors
Agnandji, S. T., Asante, K. P., Lyimo, J., Vekemans, J., Soulanoudjingar, S. S., Owusu, R., Shomari, M., Leach, A., Fernandes, J., Dosoo, D., Chikawe, M., Issifou, S., Osei‐Kwakye, K., Lievens, M., Paricek, M., Apanga, S., Mwangoka, G., Okissi, B., Kwara, E., Minja, R., Lange, J., Boahen, O., Kayan, K., Adjei, G., Chandramohan, D., Jongert, E., Demoitié, M., Dubois, M., Carter, T., Vansadia, P., Villafana, T., Sillman, M., Savarese, B., Lapierre, D., Ballou, W. R., Greenwood, B., Tanner, M., Cohen, J., Kremsner, P. G., Lell, B., Owusu‐Agyei, S., & Abdulla, S.
Venue
The Journal of Infectious Diseases
Published
2010-10
Volume
202
Issue
7
Pages
1076-1087
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2155513799
Cited by
73
References
3
FWCI
6.56
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of the Safety and Immunogenicity of the RTS,S/AS01EMalaria Candidate Vaccine When Integrated in the Expanded Program of Immunization. https://app.cochat.ai/papers/10.1086/656190
The paper
Agnandji, S. T., Asante, K. P., Lyimo, J., Vekemans, J., Soulanoudjingar, S. S., Owusu, R., Shomari, M., Leach, A., Fernandes, J., Dosoo, D., Chikawe, M., Issifou, S., Osei‐Kwakye, K., Lievens, M., Paricek, M., Apanga, S., Mwangoka, G., Okissi, B., Kwara, E., . . . Abdulla, S. (2010). Evaluation of the Safety and Immunogenicity of the RTS,S/AS01EMalaria Candidate Vaccine When Integrated in the Expanded Program of Immunization. The Journal of Infectious Diseases. https://doi.org/10.1086/656190

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.